CELYAD SA/ADR (NASDAQ:CYAD) shares reached a new 52-week low on Thursday . The company traded as low as $22.17 and last traded at $22.17, with a volume of 30684 shares trading hands. The stock had previously closed at $24.31.

A number of research firms have weighed in on CYAD. Zacks Investment Research cut shares of CELYAD SA/ADR from a “hold” rating to a “sell” rating in a research report on Monday, August 27th. ValuEngine upgraded shares of CELYAD SA/ADR from a “sell” rating to a “hold” rating in a research report on Monday, July 2nd. Finally, HC Wainwright began coverage on shares of CELYAD SA/ADR in a research report on Monday, July 2nd. They set a “buy” rating and a $45.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $46.00.

The firm has a market capitalization of $261.52 million, a P/E ratio of -6.82 and a beta of 1.52.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC grew its holdings in shares of CELYAD SA/ADR by 168.9% in the first quarter. Jane Street Group LLC now owns 16,816 shares of the company’s stock worth $586,000 after purchasing an additional 10,562 shares during the last quarter. Millennium Management LLC bought a new position in shares of CELYAD SA/ADR in the second quarter worth about $582,000. Stanley Laman Group Ltd. bought a new position in shares of CELYAD SA/ADR in the second quarter worth about $1,145,000. Finally, Victory Capital Management Inc. grew its holdings in shares of CELYAD SA/ADR by 41.9% in the second quarter. Victory Capital Management Inc. now owns 604,002 shares of the company’s stock worth $18,717,000 after purchasing an additional 178,380 shares during the last quarter. Hedge funds and other institutional investors own 7.01% of the company’s stock.

About CELYAD SA/ADR (NASDAQ:CYAD)

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.

Featured Article: Put Option

Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.